Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda's Alogliptin Among MHLW Approval Recommendations; Pfizer, Alexion Also Gain

This article was originally published in PharmAsia News

Executive Summary

Japan's First Committee on New Drugs at the Ministry of Health, Labor and Welfare recommended for approval three Takeda drugs: alogliptin and pioglitazone/metformin combination - both for type 2 diabetes - and combination drug candesartan/amlodipine for hypertension

You may also be interested in...



Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market

Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market

Takeda Submits NDA For Azilsartan With U.S. FDA To Expand Reach In Hypertension Market

Osaka-based Takeda Pharmaceutical April 28 submitted a new drug application with U.S. FDA for its angiotensin receptor blocker azilsartan and hopes to bank on the global success of candesartan to further its franchise in the hypertension treatment market

Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy

U.S. biotech firm Alexion Pharmaceuticals, which submitted a NDA in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder, could benefit from the country's practice of placing a premium on innovative drugs for orphan diseases

Related Content

UsernamePublicRestriction

Register

SC074233

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel